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CONTEXT 1 
Uncertainty exists whether the long-term use of ergot-derived dopamine agonist (DA) drugs for 2 
the treatment of hyperprolactinemia may be associated with clinically significant valvular heart 3 
disease; and whether current regulatory authority guidelines for echocardiographic screening are 4 
clinically appropriate. 5 
OBJECTIVE 6 
To provide follow-up echocardiographic data on a previously described cohort of patients treated 7 
with DA for lactotrope pituitary tumors; and to explore possible associations between structural 8 
and functional valve abnormalities with the cumulative dose of drug used. 9 
DESIGN 10 
Follow-up echocardiographic data were collected from a proportion of our previously reported 11 
cohort of patients; all had received continuous DA therapy for at least 2 years in the intervening 12 
period. Studies were performed according to British Society of Echocardiography minimum 13 
standards for adult transthoracic echocardiography. Generalised estimating equations with 14 
backward selection were used to determine odds ratios of valvular heart abnormalities according 15 
to tertiles of cumulative cabergoline dose, using the lowest tertile as the reference group. 16 
SETTING 17 
Thirteen centers of secondary/tertiary endocrine care across the United Kingdom. 18 
RESULTS 19 
There were 192 patients (81 males; median age, 51 years; interquartile range [IQR], 42–62). 20 
Median (IQR) cumulative cabergoline doses at the first and second echocardiograms were 97mg 21 
(20-377) and 232mg (91-551) respectively. Median (IQR) duration of uninterrupted cabergoline 22 
therapy between echocardiograms was 34 months (24-42). No associations were observed 23 
between cumulative doses of dopamine agonist used and the age-corrected prevalence of any 24 
valvular abnormality. 25 
CONCLUSION 26 
This large UK follow-up study does not support a clinically significant association between the 27 
use of DA for the treatment of hyperprolactinemia and cardiac valvulopathy. 28 
29 
INTRODUCTION 30 
Patients with lactotrope pituitary tumors who require medical therapy are typically treated with 31 
dopamine agonists (DAs). Amongst the ergot-derived DAs in common use, cabergoline is most 32 
widely prescribed because of its greater efficacy and better side-effect profile than 33 
bromocriptine, although some physicians still favor the latter drug for use in women attempting 34 
conception and for those in established pregnancy who require treatment to control tumor size. 35 
Following the publication of a number of case reports, cohort studies and case-controlled series 36 
describing the association of short-term, intensive high dose cabergoline therapy for Parkinson’s 37 
disease with cardiac valvulopathy1,2,2,3, guidance was issued by various medicines regulatory 38 
authorities recommending screening with transthoracic echocardiography (TTE) for all patients 39 
with hyperprolactinemic states on maintenance treatment with this class of drug4. 40 
Since then, a number of groups have contributed data to the literature in order to guide practice 41 
in this area. Most studies have reported TTE findings in modest numbers of patients with 42 
prolactinomas and compared them with healthy controls5-7,7-15. We have previously reported TTE 43 
data from a large (747 patients), multi-center, cross-sectional UK study of patients with 44 
hyperprolactinemia treated with DAs16. Patients were divided into quartiles according to 45 
cumulative DA dose, with the lowest quartile acting as the ‘reference group’ against which 46 
higher quartiles of DA ‘exposure’ were compared16. Here, longitudinal TTE findings are 47 
reported in a proportion of those patients, all of whom had received continuous DA therapy for at 48 
least 2 years in the intervening period. 49 
  50 
MATERIALS AND METHODS 51 
 52 
Patients 53 
All 28 centers participating in our original study were contacted and invited to contribute data to 54 
this follow-up study. Thirteen centers contributed anonymized data from 192 patients (median 55 
age, 51 years; interquartile range [IQR], 42–62), of which 81 were males. The remaining fifteen 56 
centres cited time and/or local financial resource constraints as the reasons for not participating 57 
in this follow-up study. Inclusion criteria for this study were that all patients must have had two 58 
TTEs, separated temporally by at least two years and that all patients should have received 59 
uninterrupted cabergoline therapy between those two studies. Demographic and clinical data 60 
collected previously was cross-checked again for this study, included age, gender, duration of 61 
treatment, maintenance dose of drug, whether the tumor was a microadenoma (≤10 mm) or 62 
macroadenoma (≥10 mm), and the presence or absence of any previous cardiac history or risk 63 
factors for cardiac disease (smoking, hypertension, diabetes mellitus, hyperlipidemia, history of 64 
rheumatic fever). Cumulative doses of cabergoline were calculated by multiplying the weekly 65 
dose by the duration of therapy; this calculation was repeated each time the patient’s dose was 66 
adjusted by the supervising physician and allowed the calculation of a total cumulative 67 
cabergoline exposure dose.  68 
 69 
Echocardiography 70 
As in our previous study, all TTE examinations were performed by fully-trained sonographers in 71 
accordance with the British Society of Echocardiography minimum dataset for a standard adult 72 
transthoracic echocardiogram17. Valve assessment included evaluation of morphology (leaflet 73 
thickening, calcification, mobility) and function of the mitral, aortic, pulmonary, and tricuspid 74 
valves in multiple views. Two-dimensional imaging was followed by color Doppler 75 
echocardiography after optimizing gain (to eliminate random speckle color from non-moving 76 
regions) and Nyquist limit (50–60 cm/s)18. Standard pulse wave and continuous wave Doppler 77 
examinations were performed. Valvular regurgitation was quantified as absent, mild, moderate, 78 
or severe by integrating multiple indices of severity4,19. As in our previous study, potentially 79 
clinically significant valvular disease (morphological or functional) was considered to be 80 
moderate or above.  81 
 82 
Statistical Analysis 83 
TTE parameters were described using medians and IQRs. The Wilcoxon signed rank test was 84 
used to compare parameters between the first and second studies. Generalised estimating 85 
equations, to take account of the repeated TTE measurements, were used to determine univariate 86 
odds ratios (ORs) for moderate or above abnormalities of any valve according to tertiles of 87 
cabergoline dose and patient characteristics. Generalised estimating equations with backwards 88 
selection were used to determine multivariate ORs. ORs were also calculated for mild or above 89 
valvular abnormalities. Statistical significance was taken as p<0.05. All analyses were performed 90 
in Stata version 13 (StataCorp, College Station, Texas, USA). 91 
 92 
The project was supported by the Clinical Endocrinology Trust. Institutional review board 93 
permission was obtained at each center. 94 
 95 
  96 
RESULTS 97 
Of the 192 patients, there were 88 (46%) with a microadenoma, 93 (48) had a macroadenoma 98 
and in the remainder it was not specified by the referring physician. Median (IQR) cumulative 99 
cabergoline doses at the time of the first and second TTEs were 97mg (20-377) and 232mg (91-100 
551) respectively. Median (IQR) weekly cabergoline dose was 0.5mg (0.5-1.0). Median (IQR) 101 
duration of uninterrupted cabergoline therapy between the two studies was 34 months (24-42).  102 
There were 11 echocardiographic abnormalities of moderate severity at the time of the first TTE. 103 
Of these, 6 had become mild by the time of the second study, 4 were unchanged and in 1 patient 104 
moderate tricuspid regurgitation was reported to have progressed to severe. There were 4 mild 105 
echocardiographic abnormalities at the first TTE that had become moderate by the time of the 106 
second (table 1). More detailed information on the 9 echocardiographic abnormalities of 107 
moderate or above severity at the second study (in 7 patients) is also presented in table 1.  108 
Calculated ORs of any valvular abnormality (thickening, restricted movement, calcification, 109 
stenosis, regurgitation, with and without the inclusion of mild lesions) by tertile of exposure to 110 
DA are shown graphically in table 2. No associations were observed between cumulative doses 111 
of cabergoline and the age-corrected prevalence of any valvular abnormality. ORs were not 112 
influenced by the presence or absence of a cardiac history, previous rheumatic fever or any of the 113 
risk factors for heart disease and no differences were observed when patients with micro- and 114 
macro-adenomas were analysed separately. 115 
  116 
DISCUSSION 117 
In this study we have performed detailed, follow-up TTE in a large cohort of patients with 118 
hyperprolactinemia who, in addition to being exposed to DA therapy before the first 119 
examination, received uninterrupted treatment for at least two years before the second. 120 
Compared to our previous report, this cohort of patients contains a greater proportion of men and 121 
patients classified as having a macroadenoma. This is likely to reflect the higher background 122 
remission rate in women and of microadenomas such that some of these originally reported 123 
patients will have discontinued DA at some stage in the intervening period and not have been 124 
eligible for inclusion in this study. A patient population enriched with men and patients with 125 
macroadenomas is a useful one to study as it contains those most likely to need to continue DA 126 
therapy for a prolonged period of time. These data do not suggest a clinically significant effect of 127 
DA therapy at ‘endocrine doses’ on cardiac valvular function during medium-term follow-up and 128 
provide further reassurance to physicians using this class of drug for this clinical indication. 129 
 130 
The background to the clinical question of the cardiac safety of DA has been extensively 131 
documented and summarised. Cabergoline binds to the same receptors (5-HT2B) that mediate 132 
carcinoid heart disease, although there is no direct relationship between plasma levels of 5-HT 133 
and presence of valvulopathy suggesting that other factors may be required for the pathogenesis 134 
of valve dysfunction20 . Although cardiac valvulopathy may occur in patients with neurological 135 
disorders currently treated with doses of cabergoline up to 3mg daily for more than 6 months1, 136 
many endocrine physicians experienced in the management of pituitary disease were surprised 137 
by the various regulatory authority recommendations for TTE surveillance in patients with 138 
hyperprolactinemia. The doses involved in the treatment of hyperprolactinemia are, typically, 139 
approximately 1/20th – 1/40th of those used in the treatment of Parkinson’s disease. Most 140 
lactotrope pituitary microadenomas occur in women, for whom either spontaneous remission or 141 
intervening pregnancies dictate that the drug is frequently prescribed for a limited period of time. 142 
Even if women require prolonged use of cabergoline for hyperprolactinemia, it is often possible 143 
to discontinue therapy at the time of the menopause. Our data suggest that the current 144 
recommendations (exclusion of cardiac valvulopathy before commencement of DA therapy; 145 
second TTE 3–6 months after starting treatment; and serial examinations at 6- to 12-month 146 
intervals while DA therapy is continued) are out of keeping with the risk of developing clinically 147 
significant valve disease. Based on estimates of the prevalence of lactotrope pituitary tumors, 148 
such a surveillance program would require an estimated 90 000 extra TTEs per year in the 149 
United Kingdom19 at a time when both public and private healthcare providers are seeking to 150 
ensure use of cardiovascular imaging is appropriate21. Non-financial implications, such as patient 151 
anxiety and inconvenience, are harder to quantify.  152 
 153 
The publication of data regarding valvulopathy in patients with Parkinson’s1 came more than two 154 
decades after the first clinical trials of DA agonist use in hyperprolactinemia22. There are major 155 
problems in designing studies to address the issue of possible cardiac valvulopathy in patients 156 
taking ‘endocrine doses’. Withholding DA therapy from patients with hyperprolactinemia 157 
(particularly women wanting to conceive) in order to perform controlled studies would clearly be 158 
unethical; and any postulated cardiac effects of DA therapy (positive or negative) would be hard 159 
to separate from any secondary changes that may occur as a consequence of normal gonadal 160 
steroid levels being restored to previously hypogonadal patients. Further, with the patent on 161 
cabergoline having expired, large-scale multi-center phase IV studies in this area are improbable. 162 
Most of the literature in this area therefore comes from single-center studies of modest numbers 163 
of DA-treated patients compared to age-matched healthy controls. The majority of those studies 164 
have provided reassuring data regarding valve function, with just three reports of increased 165 
tricuspid regurgitation (moderate in one, mild in two others) and an inconsistent relationship to 166 
the cumulative dose of drug5,7,8 167 
 168 
To our knowledge, this is the largest follow-up echocardiographic study of hyperprolactinemic 169 
patients treated with DA. Although the size is an obvious strength, as in our previous study, an 170 
obvious weakness is the lack of a true control group, with the lowest tertile of DA exposure 171 
serving as our ‘surrogate control’. In an earlier follow-up study, statistically significant increases 172 
in aortic valve calcification were observed with DA therapy, although these changes did not 173 
translate into any alterations in valve function7,23. Moreover, while grading the extent of valve 174 
calcification is an important factor in predicting outcome in AS24, visual estimation on 2D 175 
echocardiography is subjective and has high inter-observer variability25.  This could simply be 176 
that cardiac valvulopathy develops over a prolonged time period and that clinically significant 177 
functional changes (defined in most studies as moderate severity or above) cannot be detected 178 
over the timescales of the reported studies. It was for this reason that we included an analysis 179 
based on ‘mild or above severity’ as a statistically significant increase in the prevalence of mild 180 
valvular abnormalities could provide preliminary evidence of developing clinically relevant 181 
valvulopathy. We found no evidence of an increase in mild anatomical or functional 182 
valvulopathy with increasing DA exposure.  183 
 184 
Reassuring group data can sometimes conceal clinically important effects in small numbers of 185 
patients. It is for this reason that we present the details of the 9 moderate or above 186 
echocardiographic abnormalities in 7 patients seen at the second TTE; these cases illustrate some 187 
of the challenges of interpreting echocardiographic findings in this context. The median age of 188 
the 7 patients was 74; all except one patient was older than the median age of the overall cohort. 189 
Although this may suggest the observed abnormalities were age-related, this group of patients 190 
were also heavily exposed to DA; all except one patient had received a cumulative cabergoline 191 
dose above the median for the overall cohort. In case 5, for example, whilst the risk factor profile 192 
and documented history of IHD may well have been important factors in the progressive mitral 193 
regurgitation, the appearance of thickening of the valve leaflets is also compatible with DA 194 
therapy being aetiologically contributory. Determining which echocardiographic abnormalities 195 
carry clinical significance is also difficult. Current echocardiography systems such as those used 196 
in this study detect ‘physiological’ tricuspid regurgitation in almost all subjects and 197 
‘physiological’ mitral regurgitation in more than half26. Whilst ‘trivial’ and ‘mild’ regurgitation 198 
are so common, it is also recognised that significant reporter bias exists when information about 199 
the use of DA in patients undergoing surveillance TTE is provided to cardiac technicians27. 200 
Moreover, quantification, even when using recognised methodology including vena contracta 201 
and proximal isovelocity surface area, is only modestly reliable; inter-observer agreement for 202 
grading mitral regurgitation as severe or non-severe is only 0.28 between specialists working in 203 
academic hospitals28. In patients with less severe regurgitation, not only will inter-observer 204 
variability be higher but there may well be physiological variation that will cause some change in 205 
categorisation. It is not clear whether newer imaging modalities such as cardiac magnetic 206 
resonance imaging will provide more accurate or reproducible assessment of mild degrees of 207 
regurgitation29. 208 
 209 
In summary, this follow-up echocardiographic study provides further, reassuring evidence that 210 
cardiac valvulopathy is not a major clinical issue in patients with lactotrope pituitary adenomas 211 
treated with DA over this timescale. Prospective, case-controlled studies of the size and duration 212 
required formally to address this issue are unlikely to be conducted, given their prohibitive cost 213 
and logistical challenges. Although the design and duration of the published studies cannot 214 
‘exonerate’ DA of a possible role in causing cardiac valvulopathy, we suggest that the time is 215 
now appropriate for regulatory authorities to consider revising the guidelines for surveillance 216 
echocardiography in this group of patients. 217 
 218 
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